BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28865089)

  • 21. Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity.
    Rigalli JP; Ciriaci N; Arias A; Ceballos MP; Villanueva SS; Luquita MG; Mottino AD; Ghanem CI; Catania VA; Ruiz ML
    PLoS One; 2015; 10(3):e0119502. PubMed ID: 25781341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug Interactions.
    Weiss J; Gajek T; Köhler BC; Haefeli WE
    Pharmaceutics; 2016 Feb; 8(1):. PubMed ID: 26927160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction potential of the multitargeted receptor tyrosine kinase inhibitor dovitinib with drug transporters and drug metabolising enzymes assessed in vitro.
    Weiss J; Theile D; Dvorak Z; Haefeli WE
    Pharmaceutics; 2014 Dec; 6(4):632-50. PubMed ID: 25521244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential effects of the enantiomers of tamsulosin and tolterodine on P-glycoprotein and cytochrome P450 3A4.
    Doricakova A; Theile D; Weiss J; Vrzal R
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Jan; 390(1):49-59. PubMed ID: 27678410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of human hepatocyte nuclear factor 4alpha in the expression of drug-metabolizing enzymes and transporters in human hepatocytes assessed by use of small interfering RNA.
    Kamiyama Y; Matsubara T; Yoshinari K; Nagata K; Kamimura H; Yamazoe Y
    Drug Metab Pharmacokinet; 2007 Aug; 22(4):287-98. PubMed ID: 17827783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
    Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
    Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The androgen receptor antagonist enzalutamide induces apoptosis, dysregulates the heat shock protein system, and diminishes the androgen receptor and estrogen receptor β1 expression in prostate cancer cells.
    Abazid A; Martin B; Choinowski A; McNeill RV; Brandenburg LO; Ziegler P; Zimmermann U; Burchardt M; Erb H; Stope MB
    J Cell Biochem; 2019 Oct; 120(10):16711-16722. PubMed ID: 31297844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Desmethyl bosentan displays a similar in vitro interaction profile as bosentan.
    Weiss J; Baumann S; Theile D; Haefeli WE
    Pulm Pharmacol Ther; 2015 Feb; 30():80-6. PubMed ID: 25535031
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Bleasby K; Fillgrove KL; Houle R; Lu B; Palamanda J; Newton DJ; Lin M; Chan GH; Sanchez RI
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide.
    Del Re M; Fogli S; Derosa L; Massari F; De Souza P; Crucitta S; Bracarda S; Santini D; Danesi R
    Cancer Treat Rev; 2017 Apr; 55():71-82. PubMed ID: 28340451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction of Hydroxychloroquine with Pharmacokinetically Important Drug Transporters.
    Weiss J; Bajraktari-Sylejmani G; Haefeli WE
    Pharmaceutics; 2020 Sep; 12(10):. PubMed ID: 32992777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, in vitro.
    Rickert V; Haefeli WE; Weiss J
    Pulm Pharmacol Ther; 2014 Aug; 28(2):130-7. PubMed ID: 24657506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps.
    Burger H; van Tol H; Brok M; Wiemer EA; de Bruijn EA; Guetens G; de Boeck G; Sparreboom A; Verweij J; Nooter K
    Cancer Biol Ther; 2005 Jul; 4(7):747-52. PubMed ID: 15970668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).
    Kort A; van Hoppe S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Mol Pharm; 2017 Oct; 14(10):3258-3268. PubMed ID: 28880088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Shikonin upregulates the expression of drug-metabolizing enzymes and drug transporters in primary rat hepatocytes.
    Huang CS; Chen HW; Lin TY; Lin AH; Lii CK
    J Ethnopharmacol; 2018 Apr; 216():18-25. PubMed ID: 29414119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
    van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
    Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR.
    Nishimura M; Yoshitsugu H; Naito S; Hiraoka I
    Yakugaku Zasshi; 2002 May; 122(5):339-61. PubMed ID: 12040753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer.
    Shiota M; Yokomizo A; Takeuchi A; Itsumi M; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    Prostate; 2014 Jun; 74(9):959-69. PubMed ID: 24740858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of pregnane X receptor in 2-acetylaminofluorene-mediated induction of drug transport and -metabolizing enzymes in mice.
    Anapolsky A; Teng S; Dixit S; Piquette-Miller M
    Drug Metab Dispos; 2006 Mar; 34(3):405-9. PubMed ID: 16381673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro.
    Weiss J; Herzog M; Haefeli WE
    Eur J Pharmacol; 2011 Jun; 660(2-3):298-304. PubMed ID: 21501604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.